Modality
Nanobody
MOA
BiTE
Target
Aβ
Pathway
DDR
OCDACC
Development Pipeline
Preclinical
~Nov 2015
→ ~Feb 2017
Phase 1
May 2017
→ Mar 2028
Phase 1Current
NCT03638945
2,699 pts·ACC
2021-12→2028-03·Active
NCT05797016
2,517 pts·ACC
2017-05→2025-05·Active
5,216 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-05-0211mo agoInterim· ACC
2028-03-162.0y awayInterim· ACC
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P1
Active
P1
Active
Catalysts
Interim
2025-05-02 · 11mo ago
ACC
Interim
2028-03-16 · 2.0y away
ACC
Active|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03638945 | Phase 1 | ACC | Active | 2699 | PANSS |
| NCT05797016 | Phase 1 | ACC | Active | 2517 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ |